JPWO2021209775A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021209775A5 JPWO2021209775A5 JP2022562752A JP2022562752A JPWO2021209775A5 JP WO2021209775 A5 JPWO2021209775 A5 JP WO2021209775A5 JP 2022562752 A JP2022562752 A JP 2022562752A JP 2022562752 A JP2022562752 A JP 2022562752A JP WO2021209775 A5 JPWO2021209775 A5 JP WO2021209775A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- cell
- pool
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 65
- 102000036639 antigens Human genes 0.000 claims description 65
- 108091007433 antigens Proteins 0.000 claims description 65
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 38
- 230000002163 immunogen Effects 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 210000001808 exosome Anatomy 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000003708 skin melanoma Diseases 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- -1 aminoalkyl glucosaminide Chemical class 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20170255.2 | 2020-04-17 | ||
| EP20170255 | 2020-04-17 | ||
| PCT/GB2021/050940 WO2021209775A1 (en) | 2020-04-17 | 2021-04-19 | Antigen pool |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522193A JP2023522193A (ja) | 2023-05-29 |
| JPWO2021209775A5 true JPWO2021209775A5 (https=) | 2024-05-20 |
| JP2023522193A5 JP2023522193A5 (https=) | 2024-05-20 |
Family
ID=70333816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562752A Pending JP2023522193A (ja) | 2020-04-17 | 2021-04-19 | 抗原プール |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230302109A1 (https=) |
| EP (1) | EP4136096A1 (https=) |
| JP (1) | JP2023522193A (https=) |
| CN (1) | CN115667288A (https=) |
| CA (1) | CA3176754A1 (https=) |
| WO (1) | WO2021209775A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002515734A (ja) | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | 遺伝子改変された樹状細胞により媒介される免疫刺激 |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| AT502292B1 (de) * | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| EP3576751A4 (en) * | 2017-02-01 | 2021-08-04 | ModernaTX, Inc. | RNA ANTI-CANCER VACCINES |
| BR112021006941A2 (pt) * | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| AU2020302285A1 (en) * | 2019-06-28 | 2021-12-02 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2021005338A2 (en) * | 2019-07-05 | 2021-01-14 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| CN116057067A (zh) * | 2020-04-17 | 2023-05-02 | 弗朗西斯·克里克研究所有限公司 | 用于治疗黑素瘤的ctl抗原的融合蛋白 |
-
2021
- 2021-04-19 JP JP2022562752A patent/JP2023522193A/ja active Pending
- 2021-04-19 CN CN202180029092.4A patent/CN115667288A/zh active Pending
- 2021-04-19 WO PCT/GB2021/050940 patent/WO2021209775A1/en not_active Ceased
- 2021-04-19 EP EP21721983.1A patent/EP4136096A1/en active Pending
- 2021-04-19 CA CA3176754A patent/CA3176754A1/en active Pending
-
2022
- 2022-10-14 US US18/046,670 patent/US20230302109A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12533415B2 (en) | Core/shell structure platform for immunotherapy | |
| US20240293520A1 (en) | Antigenic Peptides For Prevention And Treatment Of Cancer | |
| TWI228128B (en) | Tumor antigenic peptides derived from cyclophilin B | |
| JP2022518207A (ja) | 酸化コレステロールを含有する薬物送達システム | |
| CN1320923C (zh) | 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗 | |
| CN110124018A (zh) | 一种模拟坏死肿瘤细胞的磷酸钙-脂质纳米疫苗及其应用 | |
| CN109310739A (zh) | 新抗原及其使用方法 | |
| KR20210138586A (ko) | 전립선암 치료용 rna | |
| RS65262B1 (sr) | Antigenski peptidi za prevenciju i lečenje maligniteta b ćelija | |
| KR20220010500A (ko) | 난소암 치료용 rna | |
| WO2018065628A2 (en) | Microbiota sequence variants of tumor-related antigenic epitopes | |
| WO2018084168A1 (ja) | 皮膚線維症処置剤 | |
| JPWO2000023476A1 (ja) | 新生血管特異的ペプチド | |
| JPWO2021209775A5 (https=) | ||
| US20040022813A1 (en) | Shed antigen vaccine with dendritic cells adjuvant | |
| CN112011833A (zh) | 筛选和分离肿瘤新生抗原的方法 | |
| CA3119910A1 (en) | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors | |
| JPWO2019103151A1 (ja) | 核酸を細胞内に送達するための脂質膜構造体 | |
| WO2023187127A1 (en) | Antigenic peptides for prevention and treatment of cancer | |
| JPWO2020079448A5 (https=) | ||
| JPWO2020260897A5 (https=) | ||
| JPWO2021005338A5 (https=) | ||
| US11766473B2 (en) | Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a deliver system | |
| JP2025526398A (ja) | 末梢血管疾患を治療するための組成物及び方法 | |
| HK40105746A (en) | Core/shell structure platform for immunotherapy |